Sunshine Biopharma Inc.SBFMEarnings & Financial Report
Nasdaq
SBFM Q3 2025 Key Financial Metrics
Revenue
$9.4M
Gross Profit
$3.1M
Operating Profit
$-1.1M
Net Profit
$-883.8K
Gross Margin
32.6%
Operating Margin
-11.5%
Net Margin
-9.4%
YoY Growth
11.6%
EPS
$-0.54
Financial Flow
Sunshine Biopharma Inc. Q3 2025 Financial Summary
Sunshine Biopharma Inc. reported revenue of $9.4M for Q3 2025, with a net profit of $-883.8K (-9.4% margin). Cost of goods sold was $6.3M, operating expenses totaled $4.2M.
Key Financial Metrics
| Total Revenue | $9.4M |
|---|---|
| Net Profit | $-883.8K |
| Gross Margin | 32.6% |
| Operating Margin | -11.5% |
| Report Period | Q3 2025 |
Sunshine Biopharma Inc. Annual Revenue by Year
Sunshine Biopharma Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $34.9M).
| Year | Annual Revenue |
|---|---|
| 2024 | $34.9M |
| 2023 | $24.1M |
| 2022 | $4.3M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.7M | $7.5M | $9.3M | $8.4M | $9.6M | $8.9M | $9.4M | $9.4M |
| YoY Growth | 94.9% | 54.1% | 67.3% | 41.6% | 24.9% | 18.0% | 1.2% | 11.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $27.3M | $31.9M | $29.3M | $30.1M | $30.6M | $29.2M | $32.0M | $31.5M |
| Liabilities | $6.1M | $7.1M | $5.8M | $5.0M | $7.1M | $6.5M | $6.3M | $7.3M |
| Equity | $21.2M | $24.8M | $23.5M | $25.0M | $23.5M | $22.7M | $25.7M | $24.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.7M | $-3.2M | $-4.6M | $-1.4M | $-3.4M | $-1.7M | $-1.3M | $-727800 |